Association between homocysteine and the risk of frailty: a meta-analysis
LI Jia-jia1,2, ZHAO Mei1, ZHU Li-yuan1, LI Hai-qun1
1. School of Nursing, Anhui Medical University, Hefei, Anhui 230601, China; 2. The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China
Abstract：Objective To evaluate the correlation between homocysteine and the risk of frailty through a meta-analysis. Methods The observational studies on association between homocysteine and frailty were retrieved from the databases, including Scopus, EMbase, the Cochrane Library, PubMed, Web of Science, Opengrey, CBM, CNKI, WanFang, and VIP. The retrieval time was from the establishment of the databases to April 10, 2022. According to inclusion and exclusion criterion, literature screening, information extraction and quality evaluation of literature methodology were implemented in sequence. Revman5.3 software and Stata14.0 software were used for data analysis. Results A total of 12 literatures with 12,352 participants were enrolled in this analysis, including 2,172 patients in the frailty group and 10,180 controls in the control group. Meta-analysis showed that level of homocysteine in the frailty group was higher than that in the control group (SMD=0.64, 95%CI:0.32-0.96, P<0.001). Subgroup analyses revealed that increased homocysteine levels in different study regions (Asia (SMD=0.82, 95%CI:0.22-1.42), Europe (SMD=0.37, 95%CI:0.30-0.43)), setting (hospital (SMD=1.12, 95%CI:0.46-1.76), evaluation tool for frailty (Freid frailty phenotype (SMD=0.63, 95%CI:0.06-1.20), Frail Scale (SMD=0.40, 95%CI:0.32-0.48)), and data types (original data (SMD=0.84, 95%CI:0.27-1.42), converted data (SMD=0.39, 95%CI:0.26-0.53)) were associated with an increased risk of frailty (P<0.05). Conclusion Current results suggest that high level of homocysteine may be a risk factor for frailty occurrence. However, due to the limitations of literatures’ quantity and research methods, the results need to be further explored.
李佳佳, 赵梅, 朱丽媛, 李海群. 同型半胱氨酸与衰弱发生风险关系的meta分析[J]. 实用预防医学, 2023, 30(5): 558-562.
LI Jia-jia, ZHAO Mei, ZHU Li-yuan, LI Hai-qun. Association between homocysteine and the risk of frailty: a meta-analysis. , 2023, 30(5): 558-562.
[1] 国家统计局. 中华人民共和国2020年国民经济和社会发展统计公报[J]. 中国统计, 2021, 69(3):8-22. [2] Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action[J]. J Am Med Dir Assoc, 2013, 14(6):392-397. [3] Allison R Ⅱ, Assadzandi S, Adelman M. Frailty: evaluation and management[J]. Am Fam Physician, 2021, 103(4):219-226. [4] lvarez-Sánchez N, lvarez-Ríos AI, Guerrero JM, et al. Homocysteine and C-reactive protein levels are associated with frailty in older Spaniards: the Toledo study for healthy aging[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(8):1488-1494. [5] Saedi AA, Feehan J, Phu S, et al. Current and emerging biomarkers of frailty in the elderly[J]. Clin Interv Aging, 2019, 14:389-398. [6] 柳明波, 周成萍, 黄素兰, 等. 钦州市1 005名老年人高同型半胱氨酸血症危险因素分析[J]. 实用预防医学, 2020, 27(12):1492-1495. [7] 张仲迎, 方向华, 吉训明, 等. 北京某社区1 458名中老年居民血清同型半胱氨酸水平及影响因素分析[J]. 心脑血管病防治, 2017, 17(2):133-137. [8] Swart KM, van Schoor NM, Heymans MW, et al. Elevated homocysteine levels are associated with low muscle strength and functional limitations in older persons[J]. J Nutr Health Aging, 2013, 17(6):578-584. [9] Vidoni ML, Pettee Gabriel K, Luo ST, et al. Vitamin B12 and homocysteine associations with gait speed in older adults: the Baltimore longitudinal study of aging[J]. J Nutr Health Aging, 2017, 21(10):1321-1328. [10] Vidoni ML, Pettee Gabriel K, Luo ST, et al. Relationship between homocysteine and muscle strength decline: the Baltimore longitudinal study of aging[J]. J Gerontol A Biol Sci Med Sci, 2018, 73(4):546-551. [11] 施红, 孟丽, 石婧, 等. 老年人衰弱与血液生物指标的关系研究[J]. 中华老年医学杂志, 2018, 37(12):1383-1386. [12] Guaita A, Brunelli L, Davin A, et al. Homocysteine, folic acid, cyanocobalamin, and frailty in older people: findings from the “Invece. Ab” study[J]. Front Physiol, 2021, 12:775803. [13] Lu WH, de Souto Barreto P, Rolland Y, et al. Biological and neuroimaging markers as predictors of 5-year incident frailty in older adults: a secondary analysis of the MAPT study[J]. J Gerontol A Biol Sci Med Sci, 2021, 76(11):e361-e369. [14] Hwang AC, Liu LK, Lee WJ, et al. Association of frailty and cardiometabolic risk among community-dwelling middle-aged and older people: results from the I-Lan longitudinal aging study[J]. Rejuvenation Res, 2015, 18(6):564-572. [15] Xu L, Zhang J, Shen S, et al. Clinical frailty scale and biomarkers for assessing frailty in elder inpatients in China[J]. J Nutr Health Aging, 2021, 25(1):77-83. [16] 吴粉毅. 老年住院患者的衰弱调查及影响因素分析[D]. 兰州:兰州大学, 2020. [17] 张耀杰. 同型半胱氨酸与老年衰弱的相关性研究[D]. 沈阳:中国医科大学, 2020. [18] 刘鸣, 吴红梅, 卫茂玲, 等. 系统评价、meta分析设计与实施方法[M]. 北京: 人民卫生出版社, 2011:90. [19] 林思旸. 社区老年人衰弱与高同型半胱氨酸血症的调查和相关分析[D]. 福州:福建医科大学, 2021. [20] lvarez-Sánchez N, lvarez-Ríos AI, Guerrero JM, et al. Homocysteine levels are associated with bone resorption in pre-frail and frail Spanish women: the Toledo study for healthy aging[J]. Exp Gerontol, 2018, 108:201-208. [21] Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range[J]. BMC Med Res Methodol, 2014, 14:135. [22] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605. [23] Rostom A, Dubé C, Cranney A, et al. Celiac disease[J]. Evid Rep Technol Assess (Summ), 2004, 104:1-6. [24] 杨涛, 吴丽萍, 邓湘英, 等. 老年H型高血压患者血清同型半胱氨酸和炎症因子与衰弱相关性分析[J]. 中国乡村医药, 2019, 26(8):26-27. [25] 谢军. 老年高血压患者合并衰弱的影响因素及其预后研究[D]. 合肥:安徽医科大学, 2020. [26] 李敏, 宋清扬, 王爽, 等. 老年脑梗死患者衰弱相关血清学标记物的研究[J]. 中华老年医学杂志, 2018, 37(6):641-645. [27] Wong YY, Almeida OP, Mccaul KA, et al. Homocysteine, frailty, and all-cause mortality in older men: the health in men study[J]. J Gerontol A Biol Sci Med Sci, 2013, 68(5):590-598. [28] 罗德惠, 万翔, 刘际明, 等. 如何实现从样本量、中位数、极值或四分位数到均数与标准差的转换[J]. 中国循证医学杂志, 2017, 17(11):1350-1356. [29] 石建栋, 罗德惠, 刘际明, 等. 基于中位数的荟萃分析新发展[J]. 科学观察, 2021, 16(6):82-84. [30] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3):M146-M156. [31] Rolita L, Holtzer R, Wang C, et al. Homocysteine and mobility in older adults[J]. J Am Geriatr Soc, 2010, 58(3):545-550. [32] Veeranki S, Winchester LJ, Tyagi SC. Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications[J]. Biochim Biophys Acta, 2015, 1852(5):732-741. [33] Majumder A, Singh M, Behera J, et al. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury[J]. Am J Physiol Cell Physiol, 2018, 315(5):C609-C622. [34] Ma T, Sun XH, Yao S, et al. Genetic variants of homocysteine metabolism, homocysteine, and frailty - rugao longevity and ageing study[J]. J Nutr Health Aging, 2020, 24(2):198-204. [35] Li R, Weng H, Pan Y, et al. Relationship between homocysteine levels and post-stroke cognitive impairment in female and male population: from a prospective multicenter study[J]. J Transl Int Med, 2021, 9(4):264-272.
2023, Vol. 30 
